Suppr超能文献

吡啶斯的明治疗小儿肠道假性梗阻:一名2岁女童的病例报告及文献综述

Pyridostigmine in Pediatric Intestinal Pseudo-obstruction: Case Report of a 2-year Old Girl and Literature Review.

作者信息

Di Nardo Giovanni, Viscogliosi Federica, Esposito Francesco, Stanghellini Vincenzo, Villa Maria Pia, Parisi Pasquale, Morlando Alessia, Caló Girolamo, De Giorgio Roberto

机构信息

NESMOS Department, School of Medicine and Psychology, Sapienza University of Rome, Sant'Andrea University Hospital, Rome, Italy.

Department of Translational Medical Science, Section of Pediatrics, University of Naples "Federico II," Naples, Italy.

出版信息

J Neurogastroenterol Motil. 2019 Oct 30;25(4):508-514. doi: 10.5056/jnm19078.

Abstract

Pediatric chronic intestinal pseudo-obstruction is a rare disorder characterized by a severe impairment of gastrointestinal motility leading to intestinal obstruction symptoms in the absence of mechanical causes. The diagnosis is usually clinical and diagnostic work is usually aimed to rule out mechanical obstruction and to identify any underlying diseases. Treatment is challenging and requires a multidisciplinary effort. In this manuscript we describe the youngest child successfully treated with the orally administrable, longacting, reversible anti-cholinesterase drug, pyridostigmine. Like other drugs belonging to cholinesterase inhibitors, pyridostigmine enhances gut motility by increasing acetylcholine availability in the enteric nervous system and neuro-muscular junctions. Based on the direct evidence from the reported case, we reviewed the current literature on the use of pyridostigmine in severe pediatric dysmotility focusing on intestinal pseudo-obstruction. The overall data emerged from the few published studies suggest that pyridostigmine is an effective and usually well tolerated therapeutic options for patients with intestinal pseudo-obstruction. More specifically, the main results obtained by pyridostigmine included marked reduction of abdominal distension, reduced need of parenteral nutrition, and improvement of oral feeding. The present case and review on pyridostigmine pave the way for eagerly awaited future randomized controlled studies testing the efficacy of cholinesterase inhibitors in pediatric severe gut dysmotility.

摘要

小儿慢性肠假性梗阻是一种罕见的疾病,其特征是胃肠道动力严重受损,在没有机械性病因的情况下导致肠梗阻症状。诊断通常基于临床,诊断工作通常旨在排除机械性梗阻并识别任何潜在疾病。治疗具有挑战性,需要多学科的努力。在本手稿中,我们描述了一名最年幼的儿童成功接受了口服、长效、可逆的抗胆碱酯酶药物吡啶斯的明治疗的案例。与其他胆碱酯酶抑制剂类药物一样,吡啶斯的明通过增加肠神经系统和神经肌肉接头处的乙酰胆碱可用性来增强肠道动力。基于该报告病例的直接证据,我们回顾了目前关于吡啶斯的明在严重小儿动力障碍(重点是肠假性梗阻)中应用的文献。少数已发表研究得出的总体数据表明,吡啶斯的明对于肠假性梗阻患者是一种有效且通常耐受性良好的治疗选择。更具体地说,吡啶斯的明取得的主要成果包括腹胀明显减轻、肠外营养需求减少以及经口喂养改善。本病例及关于吡啶斯的明的综述为期待已久的未来随机对照研究铺平了道路,这些研究将测试胆碱酯酶抑制剂在小儿严重肠道动力障碍中的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/608c/6786444/aa634f90f0e7/jnm-25-508-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验